cobas® SARS-CoV-2

Fast trusted SARS-CoV-2 PCR results, to enable informed care decisions

cobas® SARS-CoV-2

Help prevent the silent spread of SARS-CoV-2

SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.

 

With nearly 3.6 million deaths and nearly 171 million cases1 of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals.

 

cobas® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.

 

Relying on the rapid and accurate cobas® SARS-CoV-2 performance, healthcare providers now have the urgent answers they need to rule-in or rule-out SARS-CoV-2.

 

cobas® SARS-CoV-2 Performance*

 

Symptomatic individuals

 

LOD: 1.2 x 10-2 TCID 50/mL

Positive Agreement**

Symptomatic Positive 96.1

(95% CI: 89.0%-98.6%)

Negative Agreement**

Symptomatic Negative 96.8

(95% CI: 92.6%-98.6%)

Asymptomatic individuals


LOD: 1.2 x 10-2 TCID 50/mL

Positive Agreement**

Asymptomatic Positive 100

(95% CI: 84.5%-100%)

Negative Agreement**

Asymptomatic Negative 98.9

(95% CI: 96.2%-99.7%)

* cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System, Package Insert V01, Pleasanton, CA; Roche Molecular Systems, Inc., 2021.
** Compared to FDA EUA SARS-CoV-2 RT-PCR assays; IFU data.   
CI=confidence intervals. LOD=limit of detection.  TCID=tissue culture infective dose.

Learn more about the expanding menus of assays

 
 
 
cobas® Liat® System

 

Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.

Learn more
Drag Image to Rotate
360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list
Intended Use

Intended Use

The cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System (cobas® SARS-CoV-2) is an automated real-time RT-PCR assay intended for the rapid in vitro qualitative detection of SARS-CoV-2 in self-collected nasal swabs (collected in a healthcare setting with instruction by a healthcare provider) and healthcare provider-collected nasopharyngeal and nasal swabs from either individual suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider or from individuals without symptoms or other reasons to suspect COVID-19.

 

cobas® SARS-CoV-2 is intended for use in the detection of SARS-CoV-2 in clinical specimens. SARS-CoV-2 viral RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of active infection but do not rule out co‑infection with other pathogens not detected by the test. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.

 

Negative results do not preclude infection from SARS-CoV-2 and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

 

cobas® SARS-CoV-2 is intended for use by health professionals or trained operators who are proficient in using the cobas® Liat® System at the point of care (POC) or in a clinical laboratory setting.

References

1. http://COVID19.who.int, Last accessed 3 Jun 21

cobas® SARS-CoV-2 assay specifications

  • Instrument

    cobas® Liat® Analyser

  • Target

    SARS-CoV-2

  • Sample type

    Nasopharyngeal swab, nasal swab

  • Collection media

    Universal Transport Media (UTM), 0.85 & 0.9% saline

  • Sample extraction

    Fully automated and integrated

  • Technology

    Real-time PCR

  • Control

    Internal sample processing control, positive and negative controls

  • Time to result

    ~20 minutes

  • Reagents

    Ready-to-use, pre-packed tube format

  • Kit Storage

    2-8°C

  • Registration

    Emergency Use Authorization (EUA); CE-IVD